AbbVie boosts UK R&D with £120m+ Oxford move

AbbVie has expanded its UK research and development operations in Oxford through an investment of more than £120 million. The initiative adds a new 12,000-square-foot site, known as AbbVie Oxford, aimed at strengthening the company’s scientific footprint in the country. The investment forms part of a broader commitment to advance research in areas of high medical need and underlines the strategic importance of the UK within AbbVie’s global R&D network.

The expanded facility is focused on research in immunology, neuroscience and oncology. By concentrating on these therapeutic areas, the Oxford site is intended to support the discovery and development of new approaches for complex and chronic diseases. AbbVie said the investment is more than £120 million ($161 million).

AbbVie has said the Oxford expansion will support research to identify new disease targets and combination therapies. This work is directed at conditions where current treatment options are limited, reflecting a focus on areas with significant unmet medical need. The enhanced capabilities are expected to facilitate deeper investigation into how diseases develop and progress, enabling the design of more targeted therapies.

One area of activity is the study of how patients with certain inflammatory diseases respond to treatment over the course of their illness. This research, conducted in collaboration with the University of Oxford, aims to generate insights that can guide future drug development. By tracking patient responses over time, the collaboration is designed to inform more precise and effective treatment strategies.

The Oxford investment builds on capabilities AbbVie gained through its 2022 acquisition of Oxford-based biotechnology company DJS Antibodies. The new AbbVie Oxford site is intended to extend research that draws on antibody platform technologies and advanced discovery approaches linked to that acquisition. Integrating these capabilities into a larger R&D hub is positioned to strengthen AbbVie’s work across immunology, neuroscience and oncology.

The facility will also deepen expertise in human reverse translation, using insights from patients and clinical data to inform early-stage research. This approach supports a tighter connection between laboratory science and real-world disease biology. The combination of new physical space and prior platform technologies is intended to accelerate the identification of promising therapeutic targets.

AbbVie works with more than 100 universities and research organisations in the UK each year and is further expanding these collaborations. Partnerships with academic institutions, including the University of Oxford, are a core component of the company’s UK R&D strategy. The Oxford expansion is expected to provide additional capacity and infrastructure to support joint projects across multiple therapeutic areas.

Across its UK operations in Oxford, Maidenhead and Marlow, AbbVie employs more than 1,100 people. The enlarged Oxford site adds to this footprint, reinforcing the company’s presence in the country’s life sciences sector. The broader UK network of facilities, collaborations and staff provides a platform for long-term research programmes spanning immunology, neuroscience and oncology.